The Damaging Impact of PDUFA and Why It Should be Repealed
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
"Why are scientists coy about publishing negative data?
“a study published yesterday overturns conventional wisdom about antipsychotic drugs, which cost the United States $10 billion a year.”
Once again, the New England Journal of Medicine (July 13, 2006) has had to eat crow after it published false and misleading clinical trial findings.
It is difficult to believe this latest announcement laying claim to a new "under treated" psychiatric disorder–Intermittent Explosive Disorder (IED) is not a parody !!
The Journal of Occupational and Environmental Medicine (JOEM) has published a retraction of a 1997 fraudulent article claiming chromium does not cause
cancer.
GSK’s acknowledgement refutes the recent claims made in the official organ of the American Psychiatric Association, The American Journal of Psychiatry.
"Biological psychiatrists have looked very closely for a serotonin imbalance or dysfunction in patients with depression or obsessive compulsive disorder and, to date, it has been elusive," says Dr. Wayne Goodman, Chair of the US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee.